Updated:
AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is a publicly traded biotech firm focused on Ampligen for viral diseases and cancer — not a family office. No AUM, no investment team.
AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is a biotechnology company rather than a family office or investment manager. It focuses on developing Ampligen, an experimental therapeutic for viral infections and cancer, including chronic fatigue syndrome (ME/CFS) and pancreatic cancer. The firm does not function as an allocator of third-party capital. As a publicly traded entity (NYSE American: AIM), AIM ImmunoTech reports financials quarterly and has no disclosed AUM or investment portfolio in the traditional family office sense. Its operations are centered on clinical trials and regulatory approval pathways, not direct investments or fund commitments. The company's team includes executive officers and a board of directors, but no investment professionals managing external wealth. No recent operational events were verifiably sourced from public records beyond standard SEC filings. AIM ImmunoTech lacks the structural elements of a family office — no family wealth origin, no multi-asset deployment, and no adjacent vehicles like foundations. It is a standalone biotech firm with no connection to family office services or capital management.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Frequently asked questions
What is AIM ImmunoTech Inc.?
AIM ImmunoTech Inc. is a publicly traded biotechnology company (NYSE American: AIM) that develops therapeutics for viral diseases and cancer, including chronic fatigue syndrome. It is not a family office, asset manager, or investment firm. The company operates as a commercial entity, not a capital allocator.
Does AIM ImmunoTech Inc. manage capital for families?
No. AIM ImmunoTech Inc. is a biotechnology company, not a family office or investment manager. It does not manage capital for external families or operate any fund structures. Its financials are publicly reported through SEC filings.
Who runs investment decisions at AIM ImmunoTech Inc.?
AIM ImmunoTech Inc. does not have an investment team in the family office sense. Investment decisions are made by its executive officers and board of directors in line with corporate strategy, not for a family office portfolio.
What is AIM ImmunoTech Inc.'s main product?
The company's lead drug candidate is Ampligen, an experimental therapeutic targeting chronic fatigue syndrome, viral infections, and oncology indications including pancreatic cancer. Ampligen is not yet approved by the FDA for any indication.
How does AIM ImmunoTech Inc. generate returns?
As a publicly traded biotech firm, AIM ImmunoTech Inc. generates returns through equity appreciation and potential product approval, not through investment management or capital deployment for external parties. Its revenue is primarily from government contracts and grants.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: